Federal Circuit

PATENT, TRADE - The Federal Circuit found that imported recombinant human erythropoietin was properly held as exempt from patent infringement by the safe-harbor statute, but that defendants' uses of imports unrelated to obtaining FDA approval are not shielded. The International Trade Commission should not have dismissed the issue on jurisdictional grounds.

Read the Top 8

Sign up for the Top 8, a roundup of the day's top stories delivered directly to your inbox Monday through Friday.

Email *

Submit